Cancer Drug Pipeline Information for Patient Advocacy Groups. Breast Cancer. Route of Administration. Brand Name Generic Name Manufacturer Indication
|
|
- Amos Dickerson
- 5 years ago
- Views:
Transcription
1 Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the will be submitted to the pcodr program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that this information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document. Breast Cancer Brand Name Generic Name Manufacturer Indication Masivet masitinib AB Science Masivet masitinib AB Science Relapsed metastatic triple negative breast cancer Realpsed metastatic non-triple negative breast cancer veliparib AbbVie BRCA-deficient breast cancer veliparib AbbVie Xgeva denosumab Amgen Neoadjuvant treatment of triple negative breast cancer Prevention of bone metastases in patients with adjuvant breast cancer Xtandi enzalutamide Astellas Breast cancer Abraxane paclitaxel Celgene First-line metastatic triple-negative breast cancer CC-486 Celgene Metastatic breast cancer Halaven eribulin Eisai First/second-line HER2-negative breast cancer Subcutaneous Avastin bevacizumab Genentech Adjuvant breast cancer, HER2-negative e/ df/4q2015_rd_en.pdf ads/product-pipeline.pdf ads/product-pipeline.pdf peline.pdf Canadian Cancer Action Network
2 Avastin bevacizumab Genentech Adjuvant breast cancer, HER2-postive Kadcyla + Perjeta Kadcyla + Perjeta ipatasertib Genentech Triple-negative breast cancer SERD (GDC- 0810) trastuzumab- DM1 taselib RG6046 Genentech ER+ HER2-ngeative breast cancer Early HER2-positive breast cancer adjuvant HER2-negative, hormone receptor-positive metastatic breast cancer Metastatic ER-positive/HER2-negative breast cancer cobimetinib triple-negative breast cancer RG1273 pertuzumab RG3502 trastuzumab emtansine + pertuzumab RG3502 trastuzumab emtansine + pertuzumab RG7446 2nd line HER2-positive breast cancer early HER2-positive breast cancer, adjuvant treatment early HER2-positive breast cancer, neoadjuvant treatment metastatic triple-negative breast cancer, first-line treatment Canadian Cancer Action Network
3 Perjeta RG1273 pertuzumab buparlisib buparlisib ribociclib early HER2-positive breast cancer Novartis Novartis Novartis Metastatic breast cancer, hormone receptorpositive, aromatese inhibitor and mtor inhibitor resistant naive Metastatic breast cancer, hormone receptorpositive, aromatese inhibitor and mtor inhibitor resistant solid tumours HR+ HER2- advanced breast cancer in pre and postmenopausal women Ibrance palbociclib Pfizer Recurrent advanced breast cancer Ibrance palbociclib Pfizer High-risk early breast cancer PF Pfizer Triple-negative breast cancer Ibrance palbociclib Pfizer SAR (MM121) Postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease Sanofi Breast cancer ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf s/productpipeline/042815_pipeline_update_fin al.pdf s/productpipeline/042815_pipeline_update_fin al.pdf s/productpipeline/042815_pipeline_update_fin al.pdf OnDrugs/ApprovedDrugs/ucm ne/default.aspx Canadian Cancer Action Network
4 MLN0128 Takeda Breast cancer pipeline_ _en.pdf Canadian Cancer Action Network
5 Endocrine Cancer Lenvima lenvatinib Eisai Avastin bevacizumab Genentech High-risk carcinoid Zelboraf vemurafenib Genentech Locally recurrent or metastatic, progressive, radioactive ioidine-refractory differentiated thyroid cancer Papillary thyroid cancer, BRAF mutation positive OnDrugs/ApprovedDrugs/ucm Canadian Cancer Action Network
6 Gastrointestinal Cancer Masivet masitinib AB Science Relapsed metastatic colorectal cancer Masivet masitinib AB Science Pancreatic cancer Masivet masitinib AB Science Relapsed metastatic liver cancer Masivet masitinib AB Science Relapsed gastric cancer Masivet masitinib AB Science Masivet masitinib AB Science AMG 337 Amgen Gastric cancer Iclusig ponatinib Ariad Gastrointestinal stromal tumour, first-line treatment Gastrointestinal stromal tumour, secondline treatment Metastatic and/or unresectable gastrointestinal stromal tumors Xtandi enzalutamide Astellas Hepatocellular carcinoma Vargatef nintedanib Boehringer Ingelheim Colorectal cancer paclitaxel Celgene Adjuvant therapy for pancreatic cancer Lenvima lenvatinib Eisai Hepatocellular carcinoma MORAb-004 Eisai Colorectal cancer E7820 Eisai Colorectal cancer Cyramza ramucirumab Eli Lilly Second-line colorectal cancer e/ df/4q2015_rd_en.pdf /drug_discovery/pipeline.l ads/product-pipeline.pdf peline.pdf peline.pdf peline.pdf uments/pipeline/clinical%20develop ment%20pipeline/index.l Canadian Cancer Action Network
7 Cyramza ramucirumab Eli Lilly First-line gastric cancer Cyramza ramucirumab Eli Lilly Metastatic colorectal cancer, in combination with Folfiri, for patients whose disease has progressed on a first line bevacizumab, oxaliplatin, and fluoropyrimidine-containing regimen evofosfamide EMD Serono Pancreatic cancer Cometriq cabozantinib Exelixis ipatasertib Genentech Gastric cancer Metestatic renal cell carcinoma who have experienced disease progression following treatment with at least one ptiot VEGFR kinese inhibitor onartuzumab Genentech Metastatic colorectal cancer onartuzumab Genentech Metastatic HER2-negative gastric cancer Perjeta pertuzumab Genentech HER2-positive gastric cancer GS-5745 Gilead Gastric cancer Zydelig momelotinib Gilead Pancreatic cancer Mekinist Tafinlar panitumumab trametinib dabrafenib panitumumab trastuzumab- DM1 Novartis Colorectal cancer Advanced HER2-positive gastric cancer & uments/pipeline/clinical%20develop ment%20pipeline/index.l OnDrugs/ApprovedDrugs/ucm ch/pipeline/research.l ne ne ovartis.com/files/ meet-themanagement-2-pharma.pdf Canadian Cancer Action Network
8 Perjeta vanucizumab RG7686 RG1273 pertuzumab Somatuline lanreotide Ipsen Pharma Colorectal cancer Metastatic liver cancer advanced HER2-positive gastric cancer Unresectable, well or moderately differentiated, locally, advanced or metastatic gastroenteropancreatic neuroendocrine tumors Subcutaneous Keytruda pembrolizumab Merck Gastric cancer MLN0264 Takeda Gastric cancer MLN0264 Takeda Pancreatic cancer OnDrugs/ApprovedDrugs/ucm ne/home.l pipeline_ _en.pdf pipeline_ _en.pdf Canadian Cancer Action Network
9 Genitourinary Cancer Masivet masitinib AB Science Xtandi enzalutamide Astellas Metastatic castrate-resistent prostate cancer, first-line treament Non-metastatic castration-resistant prostate cancer Prostate cancer in patients with nonmetastatic biochemical recurrence df/4q2015_rd_en.pdf Cyramza ramucirumab Eli Lilly Second-line bladder cancer uments/pipeline/clinical%20develop ment%20pipeline/index.l Cometriq cabozantinib Exelixis Metastatic renal cell cancer ipatasertib Genentech Prostate cancer Votrient pazopanib Novartis Adjuvant therapy for renal cell cancer RG7446 RG7446 RG7446 RG7599 lifastuzumab vedotin RG7446 Second-line urothelial bladder cancer Metastatic urothelial bladder cancer Renal cell cancer, in combination with Avastin platinum-resistant ovarian cancer muscle-invasive bladder cancer, adjuvant treatment Canadian Cancer Action Network
10 Zytiga abiraterone acetate Janssen Non-metastatic castration-resistant prostate cancer Keytruda pembrolizumab Merck Bladder cancer Inlyta axitinib Pfizer Renal cell carcinoma adjuvant, in combination with Keytruda Sutent sunitinib Pfizer Renal cell carcinoma adjuvant Jevtana cabazitaxel Sanofi Metastatic prostate cancer (1L) TAK-385 Takeda Prostate cancer s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf ne/home.l s/productpipeline/042815_pipeline_update_fin al.pdf s/productpipeline/042815_pipeline_update_fin al.pdf peline/default.aspx pipeline_ _en.pdf Canadian Cancer Action Network
11 Gynecological Cancer Lynparza olaparib AstraZeneca Monotherapy for deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer for patients who have been treated with three or more prior lines of chemotherapy Lenvima lenvatinib Eisai Endometrial cancer farletuzumab Eisai Platinum-sensitive ovarian cancer Avastin bevacizumab Genentech First-line metastatic ovarian cancer lifastuzumab vedotin Genentech & Platinum-resistent ovarian cancer afuresertib Novartis Ovarian cancer Avastin bevacizumab Relapsed platinum-sensitive ovarian cancer Avastin RG435 bevacizumab 1st line metastatic ovarian cancer binimetinib Novartis Low-grade serious ovarian cancer SAR with MSC B Sanofi dual inhibitor of PI3K & mtor, pimasertib OnDrugs/ApprovedDrugs/ucm peline.pdf peline.pdf professionals/pipeline duct-pipeline-2014.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf peline/default.aspx Canadian Cancer Action Network
12 Head and Neck Cancer Masivet masitinib AB Science Relapsed metastatic head and neck cancer MEDI4736 AstraZeneca Nimoral nimorazole Azanta Nimoral nimorazole Azanta Giotrif afatinib Boehringer Ingelheim Second-line PD-L1 positive metastatic head and neck squamous cell carcinoma First-line head and neck squamous cell carcinoma, versus accelerated chemoradiation therapy First-line platinum-resistent head and neck squamous cell carcinoma, versus conventional radiation therapy Head and neck squamous cell carcinoma CC-486 Celgene Advanced nasopharyngeal cancer Keytruda pembrolizumab Merck Head and neck cancer h/our-pipeline-summary /drug_discovery/pipeline.l ads/product-pipeline.pdf ne/home.l Canadian Cancer Action Network
13 Leukemia Blincyto blinatumomab Amgen Blincyto blinatumomab Amgen Relapsed/refractory acute lymphoblastic leukemia Relapsed/refractory Philadelphia chromosone-positive (Ph+) and minimal residual disease of acute lymphoblastic leukemia ASP2215 Astellas Acute myeloid leukemia volasertib Boehringer Ingelheim Acute myeloid leukemia Revlimid lenalidomide Celgene Second-line chronic lymphocitic leukemia Vidaza azacitidine Celgene Post-induction acute myeloid leukemia maintenance Promacta eltrombopag Novartis Acute myeloid leukemia Azerra ofatumumab Novartis venetoclax venetoclax venetoclax Chronic lymphocytic leukemia, use in relapsed patients Frontline chronic lymphocytic leukemia, in combination with Gazyva Realpsed/refractory chronic lymphocytic leukemia, in combination with rituximab Relapsed/refractory chronic lymphocytic leukemia 17p deletion e/ e/ df/4q2015_rd_en.pdf /drug_discovery/pipeline.l ds/product-pipeline.pdf ads/product-pipeline.pdf duct-pipeline-2015.pdf Canadian Cancer Action Network
14 Imbruvica ibrutinib Janssen Imbruvica ibrutinib Janssen Purixan mercaptopurine NOVA Labratories midostaurin Novartis Tasigna nilotinib Novartis inotuzumab ozogamicin Pfizer Treatment naive patients with chronic lymphocytic leukemia (single agent) Frontline chronic lymphocytic leukemia, in combination with obinutuzumab Acute lymphoblastic leukemia, as part of a combination regime Acute myeloid leukemia, aggressive systemic mastocytosis Chronic myeloid leukemia treatment-free remission Acute lymphoblastic leukemia glasdegib Pfizer Acute myeloid leukemia Bosulif bosutinib Pfizer glasdegib (PF )SMO (smoothened) Pfizer Adult patients with newly diagnosed chronic phase chronic myelogenous leukemia, versus imatinib antagonist Acute Myeloid Leukemia, *Cancer s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf OnDrugs/ApprovedDrugs/ucm ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf s/productpipeline/042815_pipeline_update_fin al.pdf s/productpipeline/042815_pipeline_update_fin al.pdf s/productpipeline/042815_pipeline_update_fin al.pdf e_and_technology/product_pipeline Canadian Cancer Action Network
15 SAR3419/Mayta nsine-loaded anti-cd19 monoclonal antibody Sanofi Acute lymphoblastic leukemia, Non- Hodgkin's lymphoma ne/default.aspx Canadian Cancer Action Network
16 Lung Cancer gefitinib (IRESSA) Masivet masitinib AB Science For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Relapsed metastatic non-small cell lung cancer veliparib AbbVie Non-small cell lung cancer Xgeva denosumab Amgen Non-small cell lung cancer Subcutaneous brigatinib Ariad Tarceva erlotinib Astellas AZD9291 MEDI4736 AZD9291 MEDI4736 AstraZeneca AstraZeneca AstraZeneca AstraZeneca Locally advanced or metastatic non-small cell lung cancer First-line treatment of metastatic non-small cell lung cancer patients whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations First-line EGFR-mutated non-small cell lung cancer, versus a standard of care EGFR-TKI (gefitinib and erlotinib) Third-line PD-L1 positive metastatic nonsmall cell lung cancer Patients with advanced EGFR-mutated nonsmall cell lung cancer who also have the T790M resistance mutation after the failure of standard first-line anti-egfr treatment Locally-advanced unresectable non-small cell lung cancer OnDrugs/ApprovedDrugs/ucm e/ OnDrugs/ApprovedDrugs/ucm h/our-pipeline-summary h/our-pipeline-summary h/our-pipeline-summary h/our-pipeline-summary Canadian Cancer Action Network
17 Giotrif Vargatef Opdivo MEDI4736 AstraZeneca Adjuvant non-small cell lung cancer MEDI4736 afatinib BI nintedanib nivolumab AstraZeneca Boehringer Ingelheim Boehringer Ingelheim Boehringer Ingelheim Bristol-Myers Squibb Third-line metastatic non-small cell lung cancer Contains a monotherapy sub-study for PD- L1 positive patients lung squamous cell carcinoma Nonsquamous non-small cell lung cancer Non-small cell lung cancer Metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy CC-486 Celgene Advanced non-small cell lung cancer Halaven eribulin Eisai Non-small cell lung cancer Lenvima lenvatinib Eisai Lenvima lenvatinib Eisai Third-line monotherapy for non-small cell lung cancer Non-small cell lung cancer (RET translocations) farletuzumab Eisai Non-small cell lung cancer necitumumab Eli Lilly Squamous non-small cell lung cancer h/our-pipeline-summary h/our-pipeline-summary /drug_discovery/pipeline.l /drug_discovery/pipeline.l /drug_discovery/pipeline.l OnDrugs/ApprovedDrugs/ucm ads/product-pipeline.pdf peline.pdf peline.pdf peline.pdf peline.pdf uments/pipeline/clinical%20develop ment%20pipeline/index.l Canadian Cancer Action Network
18 Cyramza ramucirumab Eli Lilly Metastatic non-small cell lung cancer with disease progression on or after platinumbased chemotherapy, in combination with docetaxel evofosfamide EMD Serono Non-small cell lung cancer Tepotinib1 c EMD Serono Non-small cell lung cancermet kinase inhibitor Non-small cell lung cancer Avelumab EMD Serono Anti-PD-L1 mab Non-small cell lung cancer Avastin bevacizumab Genentech Adjuvant non-small cell lung cancer Tarceva erlotinib Genentech Mekinist Tafinlar Kadcyla trametinib dabrafenib RG7446 RG7446 RG7446 alectinib trastuzumab emtansine First-line metastatic non-small cell lung cancer, EGFR mutation positive Novartis Non-small cell lung cancer First-line non-squamous non-small cell lung cancer, PDL1-selected patients Second-line non-small cell lung cancer First-line non-squamous non-small cell lung cancer, in combination with chemotherapy, with or without Avastin ALK-postiive non-small cell lung cancer, first-line treatment HER2-positive advanced non-small cell lung cancer OnDrugs/ApprovedDrugs/ucm ch/pipeline/research.l ch/pipeline/research.l ch/pipeline/research.l Added duct-pipeline-2015.pdf Canadian Cancer Action Network
19 Avastin bevacizumab RG7446 taselisib RG7853 RG7446 RG7446 RG7446 RG chemo + Avastin EGFR-mutation positive non-small cell lung cancer Metastatic non-small cell lung cancer Squamous non-small cell lung cancer ALK-positive, non-small cell lung cancer, second-line treatment First-line squamous non-small cell lung cancer, PDL1-selected patients First-line squamous non-small cell lung cancer non-small cell lung cancer, adjuvant treatment, PDL1-selected patients first-line non-squamous non-small cell lung cancer Keytruda pembrolizumab Merck Non-small cell lung cancer capmatinib Novartis Non-small cell lung cancer avelumab Pfizer Second-line non-small cell lung cancer ne/home.l ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf s/productpipeline/042815_pipeline_update_fin al.pdf Canadian Cancer Action Network
20 dacomitinib Pfizer First-line, EGFR-mutant non-small cell lung cancer alisertib Takeda Small cell lung cancer s/productpipeline/042815_pipeline_update_fin al.pdf pipeline_ _en.pdf Canadian Cancer Action Network
21 Lymphoma and Myeloma brentuximab vedotin (ADCETRIS) For the post-autologous hematopoietic stem cell transplantation (auto-hsct) consolidation treatment of patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression. Masivet masitinib AB Science Relapsed multiple myeloma Masivet masitinib AB Science Relapsed peripheral T-cell lymphoma Elotuzumab AbbVie Multiple myeloma Blincyto blinatumomab Amgen Diffuse large B-cell lymphoma Kyprolis carfilzomib Amgen Xgeva denosumab Amgen Newly diagnosed multipe myeloma, in combination with melphalan and prednisone, compared to bortezomib, melphalan, and prednisone Prevention of skeletal-related events in patients with multiple myeloma Revlimid lenalidomide Celgene Diffuse large B-cell lymphoma maintenance Revlimid lenalidomide Celgene First-line diffuse large B-cell lymphoma (ABC-subtype) Revlimid lenalidomide Celgene Relapsed/refractory indolent lymphoma Revlimid lenalidomide Celgene First-line follicular lymphoma Subcutaneous Istodax romidepsin Celgene First-line peripheral T-cell lymphoma OnDrugs/ApprovedDrugs/ucm e/ e/ e/ ds/product-pipeline.pdf ds/product-pipeline.pdf ads/product-pipeline.pdf ads/product-pipeline.pdf ads/product-pipeline.pdf Canadian Cancer Action Network
22 Revlimid lenalidomide Celgene Mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomid abemaciclib Eli Lilly Mantle cell lymphoma Gazyva obinutuzumab Genentech Diffuse large B-cell lymphoma Gazyva obinutuzumab Genentech Gazyva obinutuzumab Genentech polatuzumab vedotin Genentech Zydelig idelalisib Gilead Front-line indolent non-hodgkin's lymphoma Refractory indolent non-hodgkin's lymphoma Non-Hodgkin's lymphoma and diffuse large B-cell lymphoma Relapsed refractory indolent non-hodgkin's lymphoma Zydelig momelotinib Gilead Frontline indolent non-hodgkin's lymphoma Azerra ofatumumab Novartis Follicular lymphoma relapsed after rituximab-containing therapy Gazyva obinutuzumab Diffuse large B-cell lymphoma Gazyva obinutuzumab Rituxumab-refractory indolent non- Hodgkin's lymphoma venetoclax Front-line diffuse large B-cell lymphoma venetoclax Relapsed/refractory follicular lymphoma, in combination with rituximab OnDrugs/ApprovedDrugs/ucm uments/pipeline/clinical%20develop ment%20pipeline/index.l ne ne duct-pipeline-2015.pdf Canadian Cancer Action Network
23 Gazyva RG7159 obinutuzumab daratumumab daratumumab daratumumab daratumumab front-line indolent non-hodgkin's lymphoma Janssen Janssen Janssen Janssen Imbruvica ibrutinib Janssen Imbruvica ibrutinib Janssen Imbruvica ibrutinib Janssen Farydak panobinostat Novartis Relapsed/refractory multiple myeloma, in combination with lenalidomide/dexamethasone Relapsed/refractory multiple myeloma, in combination with bortezomib/dexamethasone Frontline multiple myeloma transplantineligible patients, in combination with bortezomib, melphalan and prednisone Frontline multiple myeloma transplantineligible patients, in combination with lenalidomide and low-dose dexamethasone Treatment naive patients with mantle cell lymphoma, in combination with Bendamustine and Rituximab Relapsed/refractory indolent nn-hodgkin's lymphoma, in combination with bendamustine and rituximab or R-CHOP Newly diagnosed non-germinal centre B- cell subtype of diffuse large B-cell lymphoma, in combination with R-CHOP Relapsed or relapsed-and-refractory multiple myeloma s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf Canadian Cancer Action Network
24 Farydak panobinostat Novartis Multiple myeloma, in combination with bortezomib and dexamethasone, for patients who have received at least two prior regimens including bortezomib and an immunomodulatory agent Afinitor everolimus Novartis Diffuse large C-cell lymphoma Imbruvica ibrutinib Pharmacyclics Adcetris Adcetris Adcetris Adcetris Adcetris SAR Sanofi Multiple myeloma brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin Seattle Genetics Seattle Genetics Seattle Genetics Seattle Genetics Seattle Genetics Patients with mantle cell lymphoma who have received at least one prior therapy Frontline treatment of advanced classical Hodgkin lymphoma, plus AVD, versus ABVD Frontline treatment for mature T-cell lymphoma, in combination with CHP, versus the standard-of-care CHOP Relapsed CD30-positive cutaneous T-cell lymphoma (primary cutaneous anaplastic large cell lymphoma, mycosis fungiodes), versus investigator's choice of methrotrexate or bexarotene Patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant Frontline treatment of diffuse large B-cell lymphoma in combination with RCHOP or RHCP OnDrugs/ApprovedDrugs/ucm ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf OnDrugs/ApprovedDrugs/ucm D_Portfolio_Phase_II-I_ pdf _trials _trials _trials _trials _trials Canadian Cancer Action Network
25 Adcetris brentuximab vedotin Seattle Genetics Beleodaq belinostat Spectrum Frontline treatment of Hodgkin lymphoma in patients age 60+, as a single agent and in combination with other agents Relapsed or refractory peripheral T-cell lymphoma ixazomib Takeda Previously untreated multiple myeloma ixazomib Takeda Relapsed or refractory multiple myeloma ixazomib ixazomib Takeda Takeda Velcade bortezomib Takeda Maintenance therapy in patients with newly diagnosed multiple myeloma following autologous stem cell transplant Maintenance therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplant Frontline treatment of mantle cell lymphoma _trials OnDrugs/ApprovedDrugs/ucm pipeline_ _en.pdf pipeline_ _en.pdf pipeline_ _en.pdf pipeline_ _en.pdf pipeline_ _en.pdf Canadian Cancer Action Network
26 Melanoma Masivet masitinib AB Science Metastatic melanoma with JM mutation of c- KIT Masivet masitinib AB Science Relapsed metastatic melanoma Opdivo talimogene laherparepvec nivolumab Amgen Bristol-Myers Squibb Regionally or distantly metastatic melanoma Unresectable or metastatic melanoma and disease progression following ipilimumab and a BRAF inhibitor if BRAF V600 mutation positive Lenvima lenvatinib Eisai Melanoma Ontak Mekinist Tafinlar MORAb-004 Eisai Melanoma denileukin diftitox Eisai Melanoma pimasertib EMD Serono Melanoma evofosfamide EMD Serono Melanoma cobimetinib trametinib dabrafenib cobimetinib Exelixis Unresectable locally advanced or metastatic melanoma harbouring a BRAF V600 mutation, in combination with vemurafenib Novartis Metastatic melanoma, adjuvant therapy Zelboraf vemurafenib Metastatic melanoma - BRAF mutation positive, in combination with Zelboraf Adjuvant melanoma, BRAF mutation positive e/ OnDrugs/ApprovedDrugs/ucm peline.pdf peline.pdf peline.pdf ch/pipeline/research.l ch/pipeline/research.l _0973_xl518 duct-pipeline-2015.pdf Canadian Cancer Action Network
27 binimetinib Novartis NRAS mutant melanoma binimetinib encorafenib Novartis RAF mutant melanoma ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf Canadian Cancer Action Network
28 Neurological Cancer Masivet masitinib AB Science Relapsed glioblastoma multiforme veliparib AbbVie Brain metastasis and other cancers Avastin bevacizumab Genentech First-line glioblastoma multiforme Unituxin dinutuximab United Therapeutics High-risk neuroblastoma in combination with GM-CSF, IL-2 and 13-cis-retinoic acid, for pediatric patients who have achieved at least a partial response to prior first-line multiagent, multimodality therapy OnDrugs/ApprovedDrugs/ucm Canadian Cancer Action Network
29 Sarcoma Halaven eribulin Eisai Sarcoma MORAb-004 Eisai Sarcoma evofosfamide EMD Serono Soft-tissue sarcoma Yondelis trabectedin Janssen Soft tissue sarcoma peline.pdf peline.pdf ch/pipeline/research.l s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf Canadian Cancer Action Network
30 Other Xgeva denosumab Amgen Adults and skeletally-mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to reult in severe morbidity oprozomib Amgen Hematologic malignancies Vectibix panitumumab Amgen ABP 215 ABP 494 ABP 798 ABP 980 Amgen Amgen Amgen Amgen Chemorefractory, wild-type KRAS exon 2 mcrc The same indications as bevacizumab - colorectal cancer, non-squamous nonsmall cell lung cancer, glioblastoma, renal cell carcinoma, breast cancer and ovarian cancer The same indications as cetuximab - colorectal cancer and head and neck cancer The same indications as rituximab - non- Hodgkin's lymphoma and chronic lymphocytic leukemia The same indications as trastuzumab - HER2+ breast cancer and HER2+ positive gastric cancer Revlimid lenalidomide Celgene Myelodysplastic syndrome - deletion 5q Revlimid lenalidomide Celgene Myelodysplastic syndrome - non-deletion 5q CC-486 Celgene Lower-risk myelodysplastic syndrome CC-486 Celgene Myelodysplastic syndrome - post hypomethylating agent failure Subcutaneous OnDrugs/ApprovedDrugs/ucm e/ e/ e/ e/ e/ e/ ds/product-pipeline.pdf ds/product-pipeline.pdf ads/product-pipeline.pdf ads/product-pipeline.pdf Canadian Cancer Action Network
31 sotatercept Celgene Myleodysplastic syndrome luspatercept Celgene Myleodysplastic syndrome Subcutaneous amatuximab Eisai Mesothelioma Tepotinib1 c EMD Serono Hepatocellular cancer polatuzumab vedotin Genentech & Hematological malignancies momelotinib Gilead Myelofibrosis entospletinib Gilead Hematological malignancies Promacta eltrombopag Novartis Myelodyspastic syndromes emactuzumab ipatasertib Imbruvica ibrutinib Janssen Solid tumours Solid tumours & pigmented villonodular synovitis Previously treated adults with Waldenstrom's macroglobulinemia, in combination with Rituximab ribociclib Novartis Solid tumours ads/product-pipeline.pdf ads/product-pipeline.pdf peline.pdf ch/pipeline/research.l Added ne ne s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf Canadian Cancer Action Network
32 binimetinib Novartis Solid tumours EGF816 Novartis Solid tumours BGJ398 Novartis Solid tumours encorafenib Novartis Solid tumours sonidegib (Odomzo Capsules, Novartis Pharmaceutical s Corporation) Novartis Pharmaceuticals Corporation For the treatment of patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. avelumab Pfizer Metastatic merkel cell carcinoma Imbruvica ibrutinib Pharmacyclics Waldenstrom's macroglobulinemia ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf OnDrugs/ApprovedDrugs/ucm s/productpipeline/042815_pipeline_update_fin al.pdf OnDrugs/ApprovedDrugs/ucm Canadian Cancer Action Network
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationCancer Therapy Update in 2017
Cancer Therapy Update in 2017 Editor: Le Wang, M.D., Ph.D Medical Oncology and Hematology (Board-Certified) Ibrutinib (Imbruvica) Pharmacyclics 1 /19/2017 Lymphoma Marginal Zone Lymphoma (MZL), Relapsed/Refractory
More informationClinical Therapeutic Intelligence Report: 2015 Year in Review
Clinical Therapeutic Intelligence Report: 2015 Year in Review This issue highlights the many ground-breaking therapies approved by the U.S. Food and Drug Administration over the course of 2015. Highlights
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationClinical Therapeutic Intelligence Report: Year in Review
Clinical Therapeutic Intelligence Report: Year in Review Last year marked a productive year for oncology drug research and development with ten new oncology drugs coming to market two of which were granted
More informationOpening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationPharmacy Medical Necessity Guidelines: Oral Cancer Medications
Pharmacy Medical Necessity Guidelines: Effective: February 18, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationOral Chemotherapy Agents
Oral Chemotherapy Agents NEW ADVANCES IN TARGETED THERAPY, OVERCOMING BARRIERS AND PROMOTING ADHERENCE KATIE SIAS, PHARMD CLINICAL PHARMACY COORDINATOR HEMATOLOGY/ONCOLOGY MIDMICHIGAN MEDICAL CENTER -
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationUniversity of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationCompassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018
Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018 Het CBG kan in schrijnende gevallen toestemming verlenen voor het in de handel brengen van een geneesmiddel
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationOPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC
OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC 1 Conflicts of Interest Damon Hostin Has no real or apparent conflicts
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationNICE-approved drugs for specialities which fall outside of the services currently provided by the Trust
NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationTo register or to learn more please visit:
A Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers When Saturday, October 29, 2016 8:00 AM to 4:00 PM Where JW Marriott
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationPRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES
PRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES REAL PATIENT; ANN (ALIAS) 63 year old woman who smoked for 25 years, quit 15 years ago. Complained
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationVectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:
What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationNew Cancer Drug Update 2015/2016. Teresa Knoop, MSN, RN, AOCN Vanderbilt-Ingram Cancer Center Nashville, TN
New Cancer Drug Update 2015/2016 Teresa Knoop, MSN, RN, AOCN Vanderbilt-Ingram Cancer Center Nashville, TN Disclosures No conflicts to disclose Objectives Identify new drugs that were FDA approved for
More informationRecent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape. Perjeta. Stivarga. Marquibo. Bosulif. Xtandi. Krypolis.
Krypolis Bosulif Inlyta Erivedge Xtandi Stivarga Alimta Gleevec Marquibo Perjeta Synribo Zaltrap Recent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape By Bill Bowman, JD What a year
More information2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 33 r d Prioritization 4 t h quarter 2017 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Please note: Within this document
More informationMolecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN
FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMTN AT 513-751- 2273, EXT 27110 Phase 1 REFMAL 381 (Phase 1 open at BAM only)
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationCancer drug approvals for paediatric indications (n=43)
Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 34 th Prioritization 1 st quarter 2018 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Please note: Within this document
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationRoche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Investor Update Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal
More informationNEW DRUG FUNDING PROGRAM (NDFP) & EVIDENCE BUILDING PROGRAM (EBP) Approved Drugs and Eligibility Criteria
NEW DRUG FUNDING PROGRAM (NDFP) & EVIDENCE BUILDING PROGRAM (EBP) Approved Drugs and Eligibility Criteria The information in this document is a summary of the funding criteria for the New Drug Funding
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2017 SEIN NEO ADJUVANT Neo-RHEA : NEOadjuvant Biomarker ResearcH Study of Palbociclib in Estrogen Receptor Positive HER2 Negative Breast CAncer
More informationRoche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Media Release Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal combination
More informationHSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 27 th Prioritization 2 nd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 28 th Prioritization 3 rd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document
More informationCURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )
Leukemia AALL0932 closed after Induction CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 10.10.2017) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
More informationAfinitor. Afinitor and Afinitor Disperz (everolimus) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 7 Last Review Date: June 22, 2017 Afinitor Description Afinitor and
More informationDate of HRA. Date Site Invited. Date Site Selected. Approval. Recruited. Date
14/LO/0259 134883 RE-AKT: A randomised Phase II study of enzalutamide (MDV3100) in combination with AZD5363 in s with Metastatic Castration - Resistant Prostate Cancer Yes 08/01/2018 01/07/2016 01/07/2017
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationStudienverzeichnis Medizinische Onkologie
Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More information29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationGlobal Oncology Trends 2017
June 2017 Global Oncology Trends 2017 Advances, Complexity and Cost $ Introduction Over the past decade, there has been a paradigm shift in the treatment of cancer, driven by advances in personalized medicine
More informationNSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationHighlights from the 2017 Annual Meeting of the American Society of Clinical Oncology
Your Guide to the Latest cancer research and treatments Highlights from the 2017 Annual Meeting of the American Society of Clinical Oncology CancerCare Connect Booklet Series www.cancercare.org CANCERCARE
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationContents Please refer to Medical Policy I-40 Pertuzumab (Perjeta) for additional information.
May 2018 In This Issue Coverage Guidelines Revised for Azacitidine (Vidaza)... 3 Coverage Guidelines Revised for Fulvestrant (Faslodex)... 4 Place of Service Revised for Total Hip and Total Knee Arthroplasty...
More informationOPEN TRIALS Accruals counted until 30-April Current Accrual
Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine
More informationImmunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationH&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
More informationMedia Release. Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO. Basel, 11 May 2015
Media Release Basel, 11 May 2015 Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO Roche medicines to be featured in more than 275 abstracts during ASCO 2015 New pivotal
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationAlimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationCancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
More informationCancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship
CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Oncology Agents Rx.01.67 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some
More informationMedia Release. Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Media Release Basel, 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 19 Roche medicines are included in
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationLecture 8: Antibodies & Antibody Conjugates - targeted cell killing agents
Lecture 8: Antibodies & Antibody Conjugates - targeted cell killing agents Monoclonal antibodies can be identified quickly by the mab at the end of their name. They are can be naked or conjugated depending
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Mars 2017 SEIN ADJUVANT OLYMPIA : A Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant therapy in BRCA mutated
More information